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Massive Expansion of Antigen-Specific
CD81 T Cells during an Acute Virus Infection
have not been determined, although it has been shown
that during LCMV infection there is an increase in the
number of alloreactive and antigen cross-reactive CTL,
Eric A. Butz and Michael J. Bevan*
Howard Hughes Medical Institute
Department of Immunology
University of Washington not all of which recognize LCMV antigens (Yang and
Welsh, 1986; Nahill and Welsh, 1993). In addition to theirSeattle, Washington 98195
expanded numbers, most CD81 T cells during the acute
immune response to LCMV show signs of activation.
They are enlarged; have elevated surface expressionSummary
of CD11a, CD11b, CD44, CD49d, and the interleukin-2
receptor; and show reduced expression of CD62LDuring LCMV infection, CD81 T cells expand greatly.
(Lynch et al., 1989; McFarland et al., 1992; AnderssonBystander activation has been thought to play a role
et al., 1995).because few cells score as LCMV specific in limiting
Because of the low frequency of virus-specific CTL,dilution analysis. In contrast, we find that at least a
the large numbers of apparently activated cells, and thequarter of the CD81 cells secrete IFNg specifically in
appearance of alloreactive and cross-reactive CTL, itresponse to LCMV peptides at the peak of the response.
has been assumed that the bulk of the CD81 cells haveMoreover, by analyzing the expansion of adoptively
been activated in a bystander fashion involving cyto-transferred LCMV-specific, TCR-transgenic CD81 T
kines (Yang and Welsh, 1986; Tough and Sprent, 1996).cells in congenic hosts, we have determined that most
In support of this idea, it has been demonstrated thatof the CD81 cell expansion is virus specific. Analysis
cytokines can drive antigen-independent activation ofof the effect of the monospecific TCR-transgenic T
naive and memory phenotype T cells in vitro (Unutmazcells on the host response to three LCMV epitopes
et al., 1994). There is also evidence that CD81 T cellssuggests that CTL precursors compete for sites on
of memory phenotype may be more prone to bystanderthe APC in an epitope-specific fashion and that this
activation than naive cells (Tough and Sprent, 1994;competition determines the specificity of the re-
Tripp et al., 1995), which has led to the suggestion thatsponse.
this is a mechanism for the maintenance of CD81 T cell
memory (Beverley, 1996). It also has been suggestedIntroduction
that thecytokines expressed during the antiviral immune
response may act to amplify other coincidentally activeSpecific immune responses evolve following exposure
T cell responses that are not virus specific (Strang andto foreign antigens. According to the clonal selection
Rickinson, 1987). Similarly, it has been proposed thattheory, an antigen will stimulate cells that bear receptors
bystander activation may play a role in the initiation andspecific for the antigen, resulting in their proliferation
maintenance of autoimmune diseases by expanding theand functional activation. Virus infection can result in
numbers of autoreactive T cells and breaking anergican intense activation of the immune system, and espe-
tolerance (Rott et al., 1995; Mueller and Jenkins, 1997).cially of CD81 T cells.
In this study we have used LCMV infection of B6 miceAlthough CD81 T cells are normally present in the
as a model for studying CD81 T cell proliferation duringspleen and lymph nodes of mice in lower numbers than
the immune response to virus infection. By analyzingCD41 T cells, during many virus infections they are dis-
the frequency of cells secreting interferon-g (IFNg) inproportionately expanded and may outnumber CD41 T
response to LCMV antigens, we have correlated CTLcells (Buchmeier et al., 1980; Rubin et al., 1981; Cauda
activity with antigen-specific cell frequency and haveet al., 1987; Tripp et al., 1995; Callan et al., 1996). During
found that the number of LCMV-specific CD81 T cellslymphocytic choriomeningitis virus (LCMV) infection of
was much higher than initially expected (at least 24%B6 mice, CD81 T cells increase about 5-fold (Razvi et
of CD81 cells). By adoptively transferring T cell receptoral., 1995), and in humans there is a large increase in
(TCR)±transgenic CD81 T cells specific for an epitope ofcirculating CD81 T cells during cytomegalovirus, Ep-
LCMV into host mice and extrapolating their proliferationstein-Barr virus, and varicella-zoster virus infections
during LCMV infection to the proliferation of host cells,
(Rubin et al., 1981; Cauda et al., 1987; Callan et al.,
we have determined that at least half of the CD81 T cells
1996). As the total pool of CD81 cells expands during
present are specific for LCMV. Although a significant
the virus infection, the number of antigen-specific cyto-
expansion of non±virus-specific CD81 T cells may still
toxic T lymphocytes (CTL) also rises (Lau et al., 1994;
occur during LCMV infection, the immune response is
Selin et al., 1994; Razvi et al., 1995; Tripp et al., 1995)
much more narrowly focused on the virus than has pre-
as judged by limiting dilution analysis (LDA). However,
viously been believed. These results are more in keeping
LDA indicates that only a small number of the CD81 T
with the predictions of the clonal selection hypothesis.
cells (1 in 4000 to 1 in 50, depending on the virus) are
actually specific for the infecting virus (Lau et al., 1994; Results
Selin et al., 1994; Razvi et al., 1995; Tripp et al., 1995).
The specificities of the remainder of the CD81 T cells CD81 T Cells Expand Dramatically during
LCMV Infection
A group of three C57Bl/6 mice was intravenously in-*To whom correspondence should be addressed (e-mail:mbevan@
u.washington.edu). fected with 105 plaque-forming units (pfu) of LCMV. On
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Figure 2. Antigen-Specific Cytolytic Activity Is Proportional to the
Frequency of IFNg-Secreting Cells
Figure 1. LCMV Infection of C57Bl/6 Mice Induces Massive Expan-
(A) Erythrocyte-depleted spleen cells were prepared from a pair ofsion of CD81 T Cells
day 8 LCMV-infected B6 mice and were used to determine primary
Representative CD4 versus CD8 flow cytometry profiles of spleno- ex vivo CTL activity in an 8 hr 51Cr-release assay against EL4 target
cytes from uninfected (A) or day 8 LCMV-infected B6 mice (B). The cells uncoated or coated with the indicated LCMV peptides.
numbers beside the gating boxes indicates the percentage of live- (B) The same pool of effector cells was used in an ELISPOT assay
gated cells. d8, day 8. to determine the frequency of cells secreting IFNg in response to
LCMV epitope peptides. The number of CD81 cells was determined
by FACS analysis. Error bars indicate the standard deviation of
triplicate samples. Three additional experiments yielded similar re-day 8 of infection, when the immune response to LCMV
sults. d8, day 8.
peaks (Buchmeier et al., 1980; our unpublished data), (C) The titration of spots per well versus number of LCMV day 8
these mice and a group of three uninfected control mice splenocytes per well is shown for ELISPOT data from a separate
experiment. Splenocytes were stimulated in triplicate samples withwere sacrificed and splenocytes were prepared. For the
either control EL4 cells (open circles) or with gp33-coated EL4 cellsuninfected control mice there were 7.5 6 0.5 3 107 cells
(filled squares). Stimulation with gp276- or np396-coated EL4 cellsper spleen (mean 6 SEM); for the infected mice there
resulted in similarly linear responses (data not shown).were 1.5 6 0.2 3 108 cells per spleen. These cells were
analyzed for CD41 and CD81 cell content by two-color
flow cytometry (Figure 1). The uninfected spleen cells assay of the frequency of cells secreting IFNg in re-
contained 16% 6 1% CD81 cells and 22% 6 3% CD41 sponse to each of the three LCMV epitopes: 10.6% 6
cells; infected spleens contained 50% 6 4% CD81 cells 1.7% of CD81 cells secreted IFNg in response to gp33,
and 5% 6 2% CD41 cells. In absolute cell numbers the 10.0% 6 1.4% in response to np396, and 2.9% 6 1.2%
uninfected control mice contained an average of 1.2 6 in response to gp276. The ELISPOT response to EL4
0.8 3 107 CD81 cells and 1.7 6 0.3 3 107 CD41 cells. alone was 0.5% 6 0.3% of CD81 cells, and fewer than
Infected spleens contained 8 6 1 3 107 CD81 cells and 0.2% 6 0.04% of the CD81 cells from uninfected B6
8 6 1 3 106 CD41 cellsÐan approximately 6-fold in- mice secreted IFNg in this assay with any peptide. When
crease in the numberof CD81 cellsand a 2-folddecrease splenocytes from day 8 LCMV-infected mice werestimu-
in the number of CD41 cells. A similar increase in total lated overnight with LCMV peptide-coated EL4 cells in
cell number and CD81 cell content was also observed the presence of Brefeldin A and then analyzed by fluo-
in cells pooled from the mesenteric, brachial, axilliary, rescence-activated cell sorting (FACS), greater than
and inguinal lymph nodes of each mouse (data not 90% of the cells staining positive for IFNg were also
shown). CD81 (data not shown). For this reason, and because
the IFNg secretion is revealed only in the presence of
the major histocompatibility (MHC) class I±binding pep-Antigen-Specific Lytic Activity and Frequency
of IFNg Secretion by Primary Antiviral CD81 tides, we have presented these ELISPOT data as the
percentage of CD81 cells secreting IFNg. Also, becauseT Cells Are Proportional to One Another
The B6 CTL response to LCMV is dominated by three a plot of the number of spots per well versus the number
of splenocytes per well is linear (Figure 2C), the assayDb-restricted epitopes: gp33, gp276, and np396 (Gairin
et al., 1995). The data presented in Figure 2 show that measures only antigen-specific cells and not cytokine-
induced bystanders. From data of this type we concludethe responses to gp33 and np396 are stronger than the
response to gp276. Pooled spleen cells from pairs of that the relative frequency of CD81 T cells specific for
each LCMV epitope can be determined by titration ofmice were prepared from uninfected and day 8 LCMV-
infected mice for use as effector cells in an 8 hr 51Cr- their ability to lyse peptide coated target cells.
The aggregate number of cells secreting IFNg in re-release assay against peptide-coated EL4 target cells
(Figure 2A) and in an 18 hr IFNg ELISPOT assay against sponse to the known LCMV epitopes (gp33 1 gp276 1
np396) is 24% 6 4% of CD81 T cells in the experimentpeptide-coated EL4 cells (Figure 2B). Cells from the un-
infected mice displayed no lytic activity, and the data shown in Figure 2B. To estimate the efficiency of the
ELISPOT assay, we performed control experiments withwere omitted from Figure 2A for the sake of clarity. Cells
from the infected mice were highly lytic for gp33- and cloned anti-LCMV CTL. We were able to detect 24%±
100% of the CTL in ELISPOT assays, depending on thenp396-coated EL4 cells and less active against gp276-
coated targets. Lytic units calculated at 30% lysis were particular clone and the time during its restimulation
cycle at which it was tested (data not shown). This sug-5-fold lower for gp276 than for gp33 and np396.
These data correlate with the data from the ELISPOT gests that, although 24% of splenic CD81 T cells from
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VVflu-np±infected mice, 1.3% of the CD81 cells were
donor cells (Figure 3C), and in LCMV-infected mice,
0.8% of the CD81 cells were OT-1 cells (Figure 3D). The
lower representation of the OT-1 cells in the LCMV-
infected chimeras probably reflects a greater dilution of
these cells by the larger overall expansion of CD81 cells
that occurs during LCMV infection than occurs during
VV infection. In the VVova-infected mice, 27% of the
CD81 cells were Thy1.21 (Figure 3E), confirming that the
donor cells were capable of proliferating in the host
mice. Not only did the OT-1 cells fail to proliferate signifi-
cantly during VVflu-np or LCMV infection; there also
was no ex vivo anti-OVA257±264 cytolytic activity following
VVflu-np or LCMV infections, although such activity was
readily apparent following VVova infection (data not
shown).
TCR-Transgenic gp33-Specific CD81 T Cells
Expand Dramatically during LCMV Infection
As an independent method of tracking the number of
LCMV-specific CD81 cells at the peak of the immune
response to LCMV, we adoptively transferred unstimu-
lated, LCMV-specific TCR-transgenic T cells into host
mice and infected them with LCMV. Similar methods
have been used to follow the in vivo behavior of both
CD41 and CD81 T cells (Zimmerman et al., 1996; Kedl
and Mescher, 1997; Pape et al., 1997). P14 mice are
Figure 3. Adoptively Transferred TCR-Transgenic CD81 T Cells Do transgenic for a TCR that recognizes LCMV gp33/Db
Not Expand Nonspecifically during VV or LCMV Infection (Pircher et al., 1990). We transferred 105 P14 spleen cells
Flow cytometry profiles of pooled spleen cells from pairs of B6.PL containing 30% CD81 T cells into Thy1 congenic B6.PL
control mice (A) and B6.PL host mice that received 107 purified OT-1
host mice. These PL/P14 chimeras and B6.PL controlCD81 T cells and were injected the next day with PBS (B), VVflu-np
mice (three per group) were infected with LCMV. Spleen(C), LCMV (D), or VVova (E). Splenocytes were analyzed on day 6
cells were prepared and analyzed by flow cytometry for(A±C and E) or day 8 (D) of infection. The numbers beside the gating
boxes indicate the number of donor CD81 cells as a percentage T cell types and donor cell content on day 8 of infection.
of total CD81 cells. A repetition of the experiment yielded similar The expansion of CD81 cells for both the B6.PL and PL/
results. P14 mice (Figure 4) was identical to that observed in B6
mice (Figure 1). In control, uninfected B6.PL mice that
received 105 P14 spleen cells, 0.2% of CD81 cells wereLCMV-infected mice were detected by ELISPOT, the
of donor origin 9 days after transfer (equivalent to daytrue number of anti-LCMV CTL could be substantially
8 of LCMV infection; data not shown). However, in thegreater.
LCMV-infected PL/P14 chimeras the donor cells were
greatly expanded, reaching 23% of the CD81 cell poolTCR-Transgenic CD81 T Cells of Irrelevant
in these mice (Figure 4D). Although the total CD81 T cellSpecificity Do Not Expand Significantly
expansion appeared similar in the two sets of infectedduring Virus Infections.
mice, we wondered whether the artificially high precur-OT-1 mice are transgenic for a TCR that recognizes
sor frequency of gp33-specific CTL had substantiallyovalbumin 257±264 (OVA257-264) in the context of H-2Kb altered the overall response of the chimeras to the virus.(Hogquist et al., 1994). To see if we could emulate the
bystander proliferation of non±virus-specific CD81 T
cells during infection, we transferred 107 purified OT-1 Adoptive Transfer of P14 Splenocytes Does
Not Significantly Alter the OverallCD81 T cells into age- and sex-matched Thy1 congenic
B6.PL mice (PL/OT-1 chimeras). Mice were infected the CTL Response to LCMV
To assess the effect of donor P14 cells on the hostnext day with LCMV, VVflu-np (a recombinant vaccinia
virus [VV] expressing the H-2Kd-restricted influenza nu- response to LCMV, we studied B6.PL mice and PL/P14
chimeras that had received 103, 105, or 106 P14 spleencleoprotein epitope, NP147±155 [Yewdell et al., 1985]),
or VVova (which expresses the full-length ovalbumin cells. One day after cell transfer the mice were infected
with LCMV. Spleen cells were prepared on day 8 ofprotein [Bacik et al., 1994]). On day 6 of VV infection
and day 8 of LCMV infection, spleen cells were analyzed infection, used as effector cells in a primary CTL assay
against peptide-pulsed EL4 target cells (Figure 5), andfor donor (CD81Thy1.21) cell content (Figure 3). As ex-
pected, there were no CD81Thy1.21 cells in uninfected analyzed by FACS. Uninfected chimeras that received
105 P14 cells did not respond to LCMV peptides. Thecontrol B6.PL mice (Figure 3A), whereas 7 days after
transfer of OT-1 cells, 3% of the CD81 cells in uninfected CTL responses of the infected PL/P14 chimeras to each
of the three LCMV epitopes were essentially identicalPL/OT-1 mice were of donor origin (Figure 3B). In the
Immunity
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Figure 4. GP33-Specific TCR-Transgenic CD81 T Cells Expand Dra- Figure 5. Adoptive Transfer of a Limited Number of gp33-Specific
matically during LCMV Infection CD81 T Cells Does Not Significantly Alter the Overall Response to
Control B6.PL mice (A and C) or B6.PL mice that had received 105 gp33, gp276, or np396 during the Immune Response to LCMV
P14 spleen cells (z3 3 104 transgenic CD81 cells) 1 day earlier (B Primary CTL activity of splenocytes from uninfected B6.PL mice
and D) were infected with LCMV. After 8 days spleens were removed that received 105 P14 cells (open circles) and day 8 LCMV-infected
and assayed for CD4 versus CD8 staining (A and B) and donor mice (filled symbols) that received no P14 cells (squares), 103 P14
(CD81Thy1.21) CTL content (C and D). The numbers beside the cells (diamonds), 105 P14 cells (triangles), or 106 P14 cells (crosses)
gating boxes in (A) and (B) indicate the percentage of live gated 1 day prior to infection. Lysis was determined on day 8 of infection
cells; in (C) and (D) the numbers indicate the number of Thy1.21 by 51Cr-release assay using EL4 targets without additional peptide
donor cells as a percentage of CD81 cells. Results are from repre- (A) and EL4 pulsed with gp33 (B), gp276 (C), or np396 (D) peptides.
sentative individual mice from groups of three. In uninfected chime- Data are presented as the average specific lysis of targets by ef-
ric mice the donor cells were less than 0.5% of CD81 cells (data fectors from three individual mice per group, with standard deviation
not shown). d8, day 8. indicated by error bars (some of which fall within the symbols). Two
repetitions of the experiment yielded similar results.
to those of the infected B6.PL mice, although following
transfer of 106 P14 cells the response to gp276 was were gp276 specific. Therefore, a total of 54% of the
CD81 cells were LCMV specific on day 8 of infection.reduced (Figure 5C). In this experiment, the donor CD81
cells expanded to 1.5%, 26%, and 28% of CD81 cells
in the chimeras that received 103, 105, and 106 P14 cells, Donor P14 and Host T Cells Are Functionally
Active in PL/P14 Chimeric Micerespectively.
As another way of looking at the effect of transferring To exclude the possibility that the TCR-transgenic donor
cells were proliferating but not functional within the in-gp33-specific T cells into naive hosts, we compared
the responses to the three epitopes of LCMV in IFNg fected chimeras, control B6, B6.PL, and PL/P14 mice
that had received 104 P14 cells 1 day earlier were in-ELISPOT assays. In individual LCMV-infected B6 and
B6.PL mice, the ratio of np396-stimulated IFNg-secret- fected with LCMV, and, 8 days later, spleen cells were
prepared and treated with rabbit complement alone,ing cells to gp33-stimulated IFNg-secreting cells varied
from 0.7 to 1.7, and the ratio of gp276- to gp33-stimu- anti-Thy1.1 and complement, or anti-Thy1.2 and com-
plement and used as effectors in a 51Cr-release assaylated IFNg-secreting cells from 0.1 to 0.3 (data not
shown). In an additional experiment, groups of three PL/ (Figure 6). By flow cytometry, 13% of the CD81 cells
in the infected chimeras were of donor origin prior toP14 mice received 102, 103, 104, 105, or 106 P14 spleen
cells and were infected with LCMV the next day. The antibody treatment, and donor cells were reduced to
fewer than 0.5% of the CD81 cells by treatment withnp396 to gp33 IFNg-secreting ratios were 0.76 6 0.02,
1.0 6 0.5, 1.5 6 0.4, 1.3 6 0.3, and 1.6 6 0.5, respectively. anti-Thy1.2 and complement. As expected, the cytolytic
activity of B6 splenocytes (Figure 6A) was unaffectedThe gp276 to gp33 IFNg ratios were 0.09 6 0.03, 0.13
6 0.04, 0.16 6 0.05, 0.11 6 0.04, and 0.09 6 0.04. There- by anti-Thy1.1 treatment (Figure 6D) but was ablated
by treatment with anti-Thy1.2 (Figure 6G). Conversely,fore, addition of 30±3 3 105 unstimulated gp33-specific
CD81 T cells does not alter the choice or hierarchy of B6.PL activity (Figure 6B) was abolished by anti-Thy1.1
treatment (Figure 6E) and unaffected by anti-Thy1.2epitopes targeted in the anti-LCMV CTL response.
The FACS data from the PL/P14 mice that received treatment (Figure 6H). The overall pattern of CTL activity
of the PL/P14 chimeras (Figure 6C) was similar to the105 P14 cells indicated that at least 23%±26% of the
CD81 cells were gp33 specific. By comparing the lysis activity of the B6 and B6.PL mice (Figures 6A and 6B).
Following treatment with anti-Thy1.1 and complement,of np396- and gp276-coated targets to gp33-specific
lysis, we calculated that another 23%±26% of the CD81 all activity against gp276 and np396 was lost, while
activity against gp33, the target of the donor cells, wascells were np396 specific and that 5% of the CD81 cells
Expansion of Antiviral CD81 Cells during Infection
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Figure 6. Both Adoptively Transferred P14
and Host CD81 T Cells Are Functionally Ac-
tive in LCMV-Infected PL/P14 Chimeras
A group of three B6.PL mice received 104 P14
spleen cells. The next day the PL/P14 chime-
ras (C, F, and I) and groups of three B6 (A, D,
and G) and B6.PL (B, E, and H) mice were
infected with LCMV. On day 8 of infection,
splenocytes pooled for each group were pre-
pared and treated with rabbit complement
alone (A±C), with anti-Thy1.1 (anti-host) plus
complement (D±F), or with anti-Thy1.2 (anti-
donor) plus complement (G±I), and the ability
of the surviving cells to lyse uncoated EL4
targets and EL4 cells coated with the indi-
cated LCMV peptides was determined in a
51Cr-release assay.
reduced approximately 50% (Figure 6F). CTL activity of activities, they both are clearly antigen-specific re-
sponses of the CD81 T cells to viral epitopes. At thethe splenocytes from the chimeras against gp276 and
peak of the immune response to LCMV, when CD81 Tnp396 was unaffected by treatment with anti-Thy1.2 and
cells constitute half of the spleen (Figures 1 and 4), wecomplement, while activity against gp33 was reduced
found in ELISPOT assays that a total of 24% of the CD81approximately 50%. It thus appears that host CTL de-
T cells secrete IFNg in response to the three principlevelop normally against gp276 and np396 in the chimeras
H-2b±restricted epitopes of LCMV: gp33, gp276, andand that the CTL activity against gp33 is a 50:50 com-
np396 (Figure 2). Therefore, since the ELISPOT assayposite of host-derived and donor P14-derived CTL.
may not be 100% efficient, at least a quarter of the CD81Since half of the CTLactivity against gp33 is contained
T cells present are responding specifically to the virus.in the donor cells and they make up 13% of the CD81
In light of the earlier published reports indicating muchcells, we infer that 26% of the CD81 cells are gp33
lower CTL precursor frequencies, we became interestedspecific. Therefore, by correlating effector cell numbers
in the nature of bystander activation and its relation towith the peptide-specific CTL activity, we propose that
virus specific CTL proliferation.another 26% of the CD81 cells are np396 specific and
To see whether we could induce bystander prolifera-5% of the CD81 cells are gp276-specific, for a total of
tion of CD81 T cells of known but irrelevant specificity,57% of the CD81 cells.
we adoptively transferred TCR-transgenic OT-1 cells
into Thy1 congenic host mice, which we then infectedDiscussion
with vaccina virus or LCMV. The OT-1 CD81 T cells are
specific for Kb/OVA257±264 and do not have measurableThe Extent of Antigen-Specific versus cytotoxic, cytokine, or proliferative responses to any of
Bystander Expansion the three LCMV epitopes in vitro, nor do they respond
Following Armstrong LCMV infection of B6 mice, there to virus-infected cells (data not shown). We found that
was a large increase in the number of splenocytes and the representation of the donor cells was reduced in
in the representation of CD81 cells within the population adoptively transferred chimeras infected with LCMV or
(Figures 1 and 4). It has been determined by LDA that VVflu-np, a recombinant virus that expresses an irrele-
0.5%±2% of these CD81 cells are specific for LCMV vant influenza epitope, and was greatly increased after
(Lau et al., 1994; Razvi et al., 1995) and, by inference, infection with VVova, which expresses ovalbumin (Fig-
that the bulk of the proliferating cells are bystanders ure 3). In agreement with our results, it has also been
responding to cytokines produced during the immune reported that H-Y±specific CD81 T cells do not become
response (Yang et al., 1989; Tough et al., 1996). activated when adoptively transferred into hosts re-
We have found that the primary cytotoxic activity di- sponding to LCMV (Zarozinski and Welsh, 1997) and
rected against LCMV epitopes and the frequency of that vaccina virus infection of mice transgenic for an
CD81 cells that secrete IFNg in response to these epi- LCMV gp33-specific TCR does not lead to substantial
topes correlate well with each other (Figure 2). Although activation of the CD81 cells bearing the transgenic re-
ceptor (Ehl et al., 1997).we cannot show strictly that the same cells have both
Immunity
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Since the number of nonspecific CD81 T cells did not that the upper limit of bystander-expanded CD81 cells
is 37%, or about 2.5 times the original number of splenicappear to be significantly expanded in mice responding
to virus, we next sought to determine the degree to CD81 cells. It has been reported that the proliferation
of low-affinity CD81 T cells can be stimulated by muchwhich virus-specific CTL would proliferate in chimeric
mice that had received various numbers of gp33-spe- lower peptide densities than are required for functional
responses such as in vivo protection, cytotoxicity, orcific P14 cells (PL/P14 chimeras). When chimeras that
received 105 P14 spleen cells (z3 3 104 gp33-specific IFNg secretion (Speiser et al., 1992; Kageyama et al.,
1995; Valitutti et al., 1996). Thus, it may be that someCD81 cells) were infected with LCMV, the number of
donor cells was greatly increased by day 8 of infection, of the CD81 cells in the day 8 infected mice that we
cannot account for are, in fact, low-affinity anti-LCMVto about 24.5% of total CD81 cells. This occurred with-
out significant alteration to the total expansion of CD81 CD81 T cells rather than cells expanding as a result of
bystander effects. This would further reduce the signifi-cells or the overall CD8:CD4 ratio from that observed
in LCMV-infected B6 or B6.PL mice (Figures 1 and 4). cance of bystander-induced proliferation during LCMV
infection.Moreover, the proliferation of the donor-derived gp33-
specific cells did not alter the targeting of the other two Indirect evidence for the expansion of similarly large
numbers of antiviral CD81 T cells can be found in theepitopes in CTL assays (Figure 5). Since the cytolytic
activity is proportional to the frequency of the antigen- expansion of particular TCR Vb±bearing CD81 popula-
tions during certain infections (Cose et al., 1997). Inspecific cells (Figure 2), we can deduce that the number
of host-derived np396-specific cells must be similar to some individuals responding to Epstein-Barr virus infec-
tion (Callan et al., 1996) or to human immunodeficiencythe number of gp33-specific cells and that there must
be, in addition, approximately one fifth as many host- virus infection (Pantaleo et al., 1994), a transient, oli-
goclonal expansion of CD81 T cells expressing particu-derived gp276-specific cells. Therefore, the total num-
ber of CD81 T cells in these mice responding to the lar TCR Vb chains to as much as 40% of CD81 T cells
has been observed. Because these expansions parallelthree LCMV epitopes on day 8 of infection must be at
least 54% of the total CD81 cells. It also has been re- the rise and fall of circulating virus in the blood, be-
cause they are oligoclonal, and because different TCRported that half of the CD81 T cells express cytoplasmic
granules containing serine proteinase-1 (MTSP-1) at the Vb are expanded in different individuals, the expansions
do not appear to be superantigen driven. In one case,peak of LCMV infection (Kramer et al., 1989).
In a group of PL/P14 chimeric mice that initially re- virus-specific CTL activity could also be found in the
expanded cell population (Pantaleo et al., 1994), sug-ceived 104 P14 spleen cells (approximately 3000 trans-
genic CD81 T cells), the donor cells increased to 13% gesting that the cells were antigen specific. The signifi-
cance of these expansions is unclear because they areof the CD81 cells by day 8 of infection. Since the total
anti-gp33 activity that develops during the immune re- seen in only some individuals, but it may be that in the
usual response to infection there is an equally largesponse is the same regardless of the number of donor
cells transferred into thehost (Figure 5), the total number expansion of a polyclonal repertoire of antiviral CD81 T
cells. Our data support this model and suggest that largeof anti-gp33 CTL (host 1 donor) must also be the same.
Following antibody plus complement depletion of host expansions of antiviral CD81 T cells may be a common
feature of antiviral immune responses.or donor CTL from the day 8 spleen cells of PL/P14
chimeras that received 104 P14 (Figure 6), a comparison
of the reduction in gp33-specific cytolytic activity shows
An Estimate of Precursor Frequencythat about 50% of the CTL activity was derived from
The precursor frequency of CTL prior to antigen expo-Thy1.11 host cells and 50% of the activity was derived
sure has been determined for some antigens by LDA;from Thy1.21 donor cells. The total number of gp33-
for LCMV it has been estimated to be 1 in 560,000 (Selinspecific CTL, therefore, was 2 3 13%, or 26%. This
et al., 1994). Because the gp33-specific CTL responseimplies that another 26% of the cells must be np396
of PL/P14 chimeras that receive 104 P14 spleen cellsspecific and that 5% of the CD81 cells are gp276 spe-
(z3000 CD81 cells) is evenly divided between host- andcific. Thus, 57% of the CD81 cells are LCMV specific,
donor-derived cells, we believe that there are approxi-a figure in close agreement with the results obtained
mately 3000 gp33-specific CTL precursors in naiveafter transfer of 105 P14 cells (Figure 5).
B6.PL mouse. Since we estimate that there are approxi-Although we estimate on the basis of our adoptive
mately 3 3 107 CD81 T cells in a naive mouse, the precur-transfer studies that about half of the CD81 T cells on
sor frequency of gp33-specific CTL is about 1024. Weday 8 of infection are specific for LCMV, only a quarter
presume that the frequency of np396- and gp276-spe-of CD81 cells were detected as secreting IFNg in re-
cific precursors is roughly similar. By day 8 of LCMVsponse to the three LCMV peptides in our ELISPOT
infection we estimate that the total number of CD81 Tassays. It is possible that only half of the anti-LCMV
cells rises to about 1.5 3 108 (E. A. B., unpublishedCD81 cells are able to secrete IFNg in response to viral
data); 55%, or 8.3 3 107, are LCMV specific. This wouldantigens or that the ELISPOT assay is only 50% efficient
necessitate about 15 divisions over the 8 days of infec-at detecting IFNg-secreting cells.
tion, or 1 division every 13 hr. While rapid, this rate ofIf the non±LCMV-specific CD81 T cells of the naive
proliferation is well below the 7 hr dividing time that hasrepertoire remain largely within the spleen during LCMV
been observed for B cells in germinal centers (Liu et al.,infection, then, together with the half of the CD81 cells
1991). Since some of the P14 donor cells are probablythat are LCMV specific, they constitute 63% of the CD81
cells within the spleen on day 8 of infection. This means lost during the adoptive transfer, this is likely to be an
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Figure 7. Competition for MHC Class I±Peptide Complexes during CTL Priming
(Left) A virus-infected APC displays a large number of MHC class I±peptide complexes, indicated by the different numbers on the surface of
the cell.
(Center) When CTL precursors specific for epitopes 1 and 2 (T1 and T2) interact with the APC, they aggregate their respective target MHC±peptide
complexes at the zones of contact.
(Right) When enough T1 interact with the APC, they reduce the available MHC±peptide 1 complexes to the point where other T1 cells cannot
be primed, although cells of other specificities (T2) can still interact productively with the APC.
overestimate of the CTL precursor frequency. There is that, as we increase the number of donor cells trans-
also a delay following infection of the mice as the viral ferred from 104 to 105, the contribution of gp33-specific
proteins are generated and subsequently processed donor CD81 cells to the response does not increase
and presented by antigen-presenting cells (APC) to T 10-fold. Thus, an excess of gp33-specific precursors
cells, so the time during which the T cells expand will holds the host and donor precursor T cells of the same
be shorter than 8 days. For these reasons the real rate specificity in check while, at the same time, the host
of T cell division will be greater than our estimates. response to the other two epitopes is unaffected. From
this observation we conclude that there is an epitope-
specific regulation of the response.
Epitope-Specific Competition for the APC The APC that present the LCMV peptides to CTL pre-
Since the TCR-transgenic donor cells make up a smaller cursors are either LCMV-infected themselves or have
fraction of the total CD81 cells in the LCMV-infected
phagocytosed other infected cells and processed their
chimeras when fewer P14 cells are initially transferred,
proteins for presentation by MHC class I (Bevan, 1995).
it is clear that precursor frequency plays a large role in
Since it is inconceivable that separate APC present each
deciding which clones respond to a given epitope in the
of the three LCMV epitopes, we must conclude that
response to the virus. Thus, as greater numbers of P14
CD81 T cells compete for epitopes on the same APC.
cells are transferred they come to dominate the anti-
Figure 7 illustrates this notion by supposing that, follow-
gp33 response. However, since we can vary the precur-
ing viral infection, an APC presents a setof viral epitopessor frequency of gp33-specific CD81 T cells by more
on its surface. Due to competition with self peptidesthan 100-fold without affecting the number of gp33-
that bind MHC class I, the number of copies of eachspecific, np396-specific, or gp276-specific CTL that ulti-
epitope expressed per APC is likely to be 103 or fewermately develop, precursor frequency does not dictate
(Rammensee et al., 1993). CD81 T cells specific for anyepitope dominance in this system. Rather, it must be
epitope will take up space on the APC surface, butthat antigen presentation is limiting in the priming and
in addition to this epitope-nonspecific competition, weexpansion of the CD81 T cells.
propose that T cells occupying the APC will sequesterWhen 103±105 P14 spleen cells (representing 3 3
their own target epitopes in a specific manner (Figure102±3 3 104 CD81 cells) are transferred into naive B6.PL
7, middle). An excess of CD81 T cellsspecific for epitopehosts, there is no effect on the overall CTL response to
1 will sequester this epitope, reducing the available den-the three LCMV epitopes. At all of these doses, the level
sity from 103 per APC to a point where other T cells ofof host CTL response to np396 and gp276 is unchanged
the same specificity cannot recognize the APC (Figurefrom the response of control B6.PL mice. The total host-
7, right). At the same time, the APC still presents otherplus-donor T cell response to gp33 also remains con-
epitopes at 103 available copies per cell, so CD81 T cellsstant, but the composition of this response changes.
specific for these epitopes can continue to bind the APCFor example, at 103 cells transferred, only 1.5%±1.7%
and become activated.of the CD81 T cells are donor derived, and these make
What is the nature of the sequestration of MHC classup a small fraction of the total CTL activity against gp33.
I peptide epitopes on the APC? It may be that the TCRAt 104 cells transferred, donor-derived cells make up
and its ligand aggregate at the zone of contact of the13%±16% of total CD81 cells and account for about
two cells. This aggregation of MHC molecules could50% of the activity against gp33. At 105 cells transferred,
lead to their endocytosis by the APC. In this way thedonor CD81 cells make up 23%±26% of total CD81 cells
class I±peptide complexes would be turned over just asand dominate the anti-gp33 activity to the point of sup-
pressing host T cells of this specificity. It is noteworthy TCR complexes are turned over during T cell activation
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from Pharmingen. The 19E12 monoclonal antibody, specific for(Valitutti et al., 1995). Even without TCR-induced endo-
Thy1.1, and the 30H12 anti-Thy1.2 monoclonal antibody were pro-cytosis of MHC class I, however, it is clear that TCR
duced as ascites.engagement may hide epitopes in a specific way. What-
ever the mechanism, some degree of concentration or IFNg ELISPOT Assays
aggregation of specific class I epitopes on the APC into Cells secreting IFNg in an antigen-specific manner were detected
the zone of contact with the T cell would be required to using a standard ELISPOT assay (Miyahira et al., 1995). In brief, EL4
target cells were incubated in phosphate-buffered saline (PBS) withexplain the epitope-specific regulation of the response.
or without 1 mM peptide as indicated, washed several times, andThis model has important implications for our under-
added at 105 per well to graded numbers of erythrocyte-depletedstanding of how the epitope profile of a CD81 T cell
effector cells in 96-well Multiscreen-HA plates (Millipore, Bedford
response is controlled and suggests that the nature of MA) that had been precoated with protein G±purified R4±6A2. After
T cell priming works to diversify the epitopes targeted 20±24 hr, cells were removed; the plates were extensively washed;
by CTL responses. and the plates were developed by incubation with XMG-1.2-biotin,
followed by streptavidin±horseradish peroxidase and diaminobenzi-
dine (Sigma, St. Louis, MO).Experimental Procedures
Primary Ex Vivo Chromium Release AssaysMice
Target cells were prepared by incubation for 1±2 hr with or withoutC57Bl/6 (B6) mice were purchased from Taconic Farms (German-
peptide in the presence of sodium 51Cr-chromate, washed threetown, PA). Thy1 congenic B6.PL-Thy1a/Cy (B6.PL) mice were pur-
times in PBS and resuspended in RP10. For the assay, 104 targetchased from Jackson Laboratories (Bar Harbor, ME), and anti-Db/
cells were added to 96-well round-bottom plates along with differentLCMV GP-1 (33±41) TCR-transgenic P14 mice on a B6 background
numbers of erythrocyte-depleted effector cells in a total volume of(Pircher et al., 1990) were purchased from Jackson Laboratories
200 ml. After 8 hr, 100 ml of supernatant was removed and counted inand then bred in the University of Washington specific pathogen±
a Wallac 1470 Wizard g-counter (Wallac Oy, Turku, Finland). Specificfree animal facilities. Anti-Kb/chicken OVA257±264 TCR-transgenicOT-1
lysis was calculated as ([experimental release 2 spontaneous re-mice on a B6 background have been described elsewhere (Hogquist
lease]/[maximum release 2 spontaneous release]) 3 100%. Sponta-et al., 1994) and were bred in our specific pathogen±free animal
neous release was determined for target cells in medium alone, andfacilities. All mice used in these studies were 1- to 4-month-old
maximum release was determined by incubating target cells in 1%females.
Triton X-100. Spontaneous release was typically 10%±20%. Lytic
units were calculated as the number of effector cells required toCell Lines
achieve 30% lysis of target cells.EL4 (ATCC TIB-41) are a B6-derived (H-2b), MHC class II2 thymoma
In some experiments donor or host effector T cells were depletedcell line and were maintained in RP10 (RPMI 1640 supplemented
by incubating spleen cell suspensions with medium alone, with 5with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, and
mg/ml anti-Thy1.1 antibody (19E12), or with 10 mg/ml anti-Thy1.2antibiotics).
(30H12) on ice for 30 min followed by addition of rabbit complement
(Low-Tox M, Cedarlane, Westbury, NY) and incubation for 30 minViruses
at 378C.The Armstrong 53b strain of LCMV was originally obtained from
Peter J. Southern (University of Minnesota, Minneapolis, MN) and
Acknowledgmentswas grown on BHK-21 cells (ATCC CCL-10) and titered on Vero
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